

Neuro-protective combination for treating cerebral ischaemia - contains a 5-HT1A receptor agonist and 5-HT2 receptor antagonist**Publication number:** DE4039631 (A1)**Publication date:** 1992-06-17**Inventor(s):** BODE-GREUEL KERSTIN DR [DE]**Applicant(s):** TROPONWERKE GMBH & CO KG [DE]**Classification:****- international:** A61K31/445; A61K31/505; A61K31/54; A61K45/06; A61K31/445; A61K31/505; A61K31/54; A61K45/00; (IPC1-7): A61K31/40; A61K31/445; A61K31/495; A61K31/645**- European:** A61K31/445; A61K31/505; A61K31/54; A61K45/06**Application number:** DE19904039631 19901212**Priority number(s):** DE19904039631 19901212**Abstract of DE 4039631 (A1)**

A combination prepn. consists of (A) an active ingredient with a serotonin agonistic effect, which has a bonding strength on 5-HT 1A receptors smaller than 10000 nmol/l. and (B) an active ingredient with a serotonin antagonistic effect which has a bonding strength on 5-HT2 receptors smaller than 1000 nmol/l. (A) is Ipsapirone, Gepirone or Buspirone and (B) is ketanserin. Other suitable components B are Pipamperone, Spiperone, Ritanserin or Pirenperine. Wt. ratio A:B is 1:0.01-100. USE/ADVANTAGE - The combination can be used in neuroprotective pharmaceuticals esp. in the treatment of cerebral ischaemia. The neuroprotective effect of (B) is increased synergistically by (A). Suitable daily doses of the combination are 0.01-100 (esp. 1-50) mg/kg

Data supplied from the esp@cenet database — Worldwide